Pierobon M, Robert NJ, Northfelt DW, Jahanzeb M, Wong S, Hodge KA, Aldrich J, Craig DW, Liotta LA, Wulfkuhle JD, Gallagher RI, Arguello D, Conrad A, Kemkes AC, Loesch DM, Vocila L, Dunetz B, Carpten JD, Petricoin EF, Anthony SP.
Study Primary Objective
The aim of this prospective pilot study was to explore if treatment selection based on Multi-omic Profiling (MoP) provides clinical benefits superior to empiric treatment selection in progressive metastatic breast cancers (MBC).
- This study confirmed the unique role of MoP in selecting effective treatments for MBC.
- This approach provided clinical benefits for 56% of previously treated MBC patients, which met the primary objective of the study.
- This study also suggests that irinotecan may be an under-developed drug for MBC patients.
- As such, this approach merits further investigation.